Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Aug:158:104898.
doi: 10.1016/j.phrs.2020.104898. Epub 2020 May 11.

Does lopinavir really inhibit SARS-CoV-2?

Dario Cattaneo  1 , Dario Cattaneo  2 , Cristina Gervasoni  3 , Mario Corbellino  4 , Massimo Galli  4 , Agostino Riva  4 , Cristina Gervasoni  4 , Emilio Clementi  5 , Emilio Clementi  6
Affiliations
Comment

Does lopinavir really inhibit SARS-CoV-2?

Dario Cattaneo et al. Pharmacol Res. 2020 Aug.
No abstract available

PubMed Disclaimer

Figures

None
Graphical abstract
See this image and copyright information in PMC

Comment on

References

    1. Ford N., Vitoria M., Rangaraj A., Norris S.L., Calmy A., Doherty M. Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19: initial assessment. J. Int. AIDS Soc. 2020;23(4) doi: 10.1002/jia2.25489. - DOI - PMC - PubMed
    1. Ye X.T., Luo Y.L., Xia S.C., Sun Q.F., Ding J.G., Zhou Y., Chen W., Wang X.F., Zhang W.W., Du W.J., Ruan Z.W., Hong L. Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019. Eur. Rev. Med. Pharmacol. Sci. 2020;24:3390–3396. - PubMed
    1. Cao B., Wang Y., Wen D., Liu W., Wang J., Fan G., Ruan L., Song B., Cai Y., Wei M., Li X., Xia J., Chen N., Xiang J., Yu T., Bai T., Xie X., Zhang L., Li C., Yuan Y., Chen H., Li H., Huang H., Tu S., Gong F., Liu Y., Wei Y., Dong C., Zhou F., Gu X., Xu J., Liu Z., Zhang Y., Li H., Shang L., Wang K., Li K., Zhou X., Dong X., Qu Z., Lu S., Hu X., Ruan S., Luo S., Wu J., Peng L., Cheng F., Pan L., Zou J., Jia C., Wang J., Liu X., Wang S., Wu X., Ge Q., He J., Zhan H., Qiu F., Guo L., Huang C., Jaki T., Hayden F.G., Horby P.W., Zhang D., Wang C. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N. Engl. J. Med. 2020 doi: 10.1056/NEJMoa2001282. [Epub ahead of print] - DOI - PMC - PubMed
    1. Wu C.Y., Jan J.T., Ma S.H., Kuo C.J., Juan H.F., Cheng Y.S., Hsu H.H., Huang H.C., Wu D., Brik A., Liang F.S., Liu R.S., Fang J.M., Chen S.T., Liang P.H., Wong C.H. Small molecules targeting severe acute respiratory syndrome human coronavirus. Proc Natl Acad Sci U S A. 2004;101:10012–10017. - PMC - PubMed
    1. Choy K.T., Yin-Lam Wong A., Kaewpreedee P., Sia S.F., Chen D., Hui K.P.Y., Chu D.K.W., Chan M.C.W., Cheung P.P., Huang X., Peiris M., Yen H.L. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res. 2020 doi: 10.1016/j.antiviral.2020.104786. [Epub ahead of print] - DOI - PMC - PubMed